Our experts will be onsite at JP Morgan (San Francisco, January 8-11). Join them to explore commercialization models and options for your assets. EVERSANA offers alternatives to selling, out-licensing or launching internally. Join us for a conversation.
Schedule a meeting for:
Emerging Biotech exploring their first launch
Pharma Executives with established product portfolio
Investors seeking predictability
Since its launch in 2018, EVERSANA has built the industry’s first fully integrated commercialization solution, serving more than 650 partners ranging from established pharmaceutical companies to emerging start-ups.
EVERSANA’s global commercial services are recognized for improving the launch and long-term in-market success for products across more than 50 therapeutic indications, including oncology, as well as advanced digital therapeutics.
Explore a few of our commercial models:
- EVERSANA COMPLETE COMMERCIALIZATION – full access to ready-to-deploy, high-performance commercialization and distribution engine; mitigate the risk of having to build commercial infrastructure
- EVERSANA REIGNITE – built for large pharma established brand portfolios – Maximize product value before its loss of exclusivity, and optimize revenue at the late stages of the product life cycle